Zacks Investment Research has recently initiated coverage of Utah Medical Products, Inc. UTMD with a Neutral recommendation. This report highlights the company's strong positioning in the growing ...
The 2Q percentage decline in consolidated revenues was less than for 1H primarily because the period-to-period decline in UTMD sales to its previously major biopharmaceutical OEM customer PendoTECH ...
SALT LAKE CITY, Jan. 30, 2020 (GLOBE NEWSWIRE) -- In the final calendar quarter (4Q) of 2019, Utah Medical Products, Inc. (Nasdaq: UTMD) began to realize accretive profits net of the quarterly ...
SALT LAKE CITY, UT / ACCESS Newswire / October 23, 2025 / Utah Medical Products, Inc. (UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2025 financial results that were ...
1 Day UTMD 0.24% DJIA -0.20% Russell 2K -0.50% Health Care/Life Sciences -0.42% ...
SALT LAKE CITY, UT / ACCESS Newswire / July 24, 2025 / Utah Medical Products, Inc. [Nasdaq:UTMD] reports second calendar quarter (2Q) and first half (1H) 2025 financial results which are consistent ...
1 Day UTMD 0.56% DJIA 0.25% Russell 2K 0.56% Health Care/Life Sciences -0.37% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results